These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30294606)

  • 1. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status.
    Kanat O; Ertas H; Caner B
    World J Clin Cases; 2018 Oct; 6(11):418-425. PubMed ID: 30294606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
    Takegawa N; Yonesaka K
    Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
    Martinelli E; Troiani T; Sforza V; Martini G; Cardone C; Vitiello PP; Ciardiello D; Rachiglio AM; Normanno N; Sartore-Bianchi A; Marsoni S; Bardelli A; Siena S; Ciardiello F
    ESMO Open; 2018; 3(1):e000299. PubMed ID: 29387480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remarkable Response of
    Li HS; Yang LL; Zhang MY; Cheng K; Chen Y; Liu JY
    Front Oncol; 2020; 10():548867. PubMed ID: 33194604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with
    Khelwatty SA; Puvanenthiran S; Essapen S; Bagwan I; Seddon AM; Modjtahedi H
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 targeted therapy in colorectal cancer: New horizons.
    Suwaidan AA; Lau DK; Chau I
    Cancer Treat Rev; 2022 Apr; 105():102363. PubMed ID: 35228040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
    La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
    Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.
    Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
    Avicenna J Med Biotechnol; 2015; 7(4):134-44. PubMed ID: 26605007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
    Lee MS; Kopetz S
    Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
    Fakih MG
    Oncologist; 2018 Apr; 23(4):474-477. PubMed ID: 29330210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
    Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.